Revvity for Life Sciences’ Post

View organization page for Revvity for Life Sciences, graphic

49,555 followers

Ischemic stroke is a global health challenge for its high rate of mortality, but as a leading cause of long-term adult disability. There is a pressing need for research that continues to push the development of pharmacotherapy options for those that may fall outside the gold standard tPA treatment, which works by breaking up blood clots. AP39, a mitochondria-targeted H2S donor is an interesting pre-clinical candidate for its prophylactic and neuroprotective properties in post-ischemia. Read more. For research use only. Not for use in diagnostic procedures. http://ms.spr.ly/6046YjXaI

To view or add a comment, sign in

Explore topics